QurCan Therapeutics
PrivateLast Round
Accelerator
Oct 5, 2022
Total Funding Raised
$6.15M
Company Overview
QurCan Therapeutics operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was an Accelerator round in October 2022.
QurCan Therapeutics is a biotechnology company that develops a proprietary nanoparticle drug delivery platform for targeted therapeutics to treat cancer and neurodegenerative diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
QurCan Therapeutics Comparables
Compare QurCan Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Nanite, Inc. | 86% | |
| CereCura Nanotherapeutics | 84% | |
| Flashpoint Therapeutics | 83% |
For institutional investors. Book with your work email.
QurCan Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Accelerator | Oct 5, 2022 | ||||
| Grant | Sep 1, 2022 | ||||
| Seed | May 17, 2021 | ||||
| Seed | Jan 28, 2020 | ||||
| Seed | Apr 8, 2019 | ||||
Grant | Mar 21, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
QurCan Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Ontario Brain Institute | Grant, Seed |
| MEDTEQ+ | Seed |
| Mission BioCapital | Accelerator |
| National Research Council of Canada | Grant |
| Pfizer | Accelerator |
| FACIT | Seed |
| Ontario Centre of Innovation | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 1, 2022
$76K grant received from National Research Council of Canada.
- May 17, 2021
$3M round led by FACIT
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withSep 16, 2026
On Sep 15th '26 in Canada, QurCan and Lilly Group announced an exclusive collaboration to develop genetic medicine therapeutics for central and peripheral nervous system diseases, with QurCan optimizing therapeutics and Lilly Group leading further research, clinical development, and commercialization.
- is_developingSep 16, 2026
QurCan develops genetic medicine therapeutics for diseases of the central and peripheral nervous systems with Eli Lilly and Company under an exclusive research and collaboration agreement, using its TERP polymer-lipid nanoparticle platform while Lilly oversees further research and commercialisation.
- is_developingSep 15, 2026
QurCan and Lilly will collaborate on multiple research programs to develop PLNP-enabled genetic medicine therapeutics for CNS and PNS delivery, with QurCan optimizing the therapeutics through its TERP platform and Lilly leading further research, clinical development, and commercialization.
For institutional investors. Book with your work email.
QurCan Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about QurCan Therapeutics's valuation, stock price, and market status.
Is QurCan Therapeutics a public or private company?
QurCan Therapeutics is a private company.
What is the current stock price of QurCan Therapeutics?
QurCan Therapeutics is a private company, so its shares have no public market price. Caplight tracks QurCan Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is QurCan Therapeutics worth (valuation)?
Valuation information for QurCan Therapeutics is not publicly available.
Can I buy QurCan Therapeutics stock?
QurCan Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was QurCan Therapeutics's last funding round?
QurCan Therapeutics's most recent funding round was Accelerator on October 5, 2022.
Who are the main investors in QurCan Therapeutics?
Key investors in QurCan Therapeutics include FACIT.
Will QurCan Therapeutics IPO soon?
No public IPO plans have been announced for QurCan Therapeutics.
How can I track QurCan Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in QurCan Therapeutics's shares on secondary markets.